September 11th 2025
Oxford’s Prof Katrina Lythgoe and Mahan Ghafari, DPhil, report ONS-CIS data on 576 persistent UK infections with rapid within-host evolution and rare transmission after one month.
September 10th 2025
William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.
September 3rd 2025
Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.
September 2nd 2025
Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.
August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
Double Digit Decline in Infectious Disease Research During Coronavirus Pandemic
September 16th 2020Incredible resources and effort have been put into the COVID-19 response, but other infectious disease priorities have also been displaced. Patrick Howie, CEO of a firm which aggregates clinical analysis and data, explains.
Watch
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831